Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9427-26-R-E020

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

AN13

Additional Details
Set Aside

None

Place of Performance

Frederick, Maryland, UNITED STATES

SourceSAM
The Defense Health Agency (DHA), operating under the Department of Defense, has issued a solicitation for the development of a prototype product aimed at Battlefield Wound Infection Prevention and Treatment (BWI P&T) through a Barrier Combination (BC) solution. This procurement, identified by HT9427-26-R-E020, is managed by the Defense Health Agency Contracting Activity (DHACA) in support of the Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection and Acute Care Program Management Office (WPAC PMO), located in Frederick, Maryland at Fort Detrick. The primary objective of this solicitation is to advance a novel wound treatment product that integrates both a physical barrier and antimicrobial and/or antifungal properties. The envisioned Barrier Combination product must serve as a protective layer for battlefield wounds, simultaneously releasing antibacterial and/or antifungal agents to prevent the spread of infectious organisms and mitigate the risk of systemic infections. The final deliverable is required to be a combination wound treatment with a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties. Importantly, the product must achieve U.S. Food and Drug Administration (FDA) approval or clearance, ensuring its suitability for use in military medical contexts. This procurement will result in a single award under the authority of prototype Other Transaction Authority (pOTA), as specified in 10 U.S.C. 4022. The solicitation is classified under NAICS Code 541715, which pertains to Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and Product Service Code AN13. The place of performance is Frederick, Maryland, USA. The contracting entity is the Defense Health Agency, a federal office within the Department of Defense. The primary point of contact for this opportunity is Bryan Heickman, who can be reached at [email protected]. The solicitation remains active, with a proposal response deadline set for November 20, 2026, at 17:11 Eastern Time. Offerors should note several amendments to the solicitation, including extensions to the proposal due date and updates to attachments such as Offeror questions and Government responses, Statement of Objectives (SOO), Draft Agreement Terms & Conditions, SOW Template, and CMMC Level I Self-Assessment Instructions. These documents provide further guidance and clarification for prospective contractors. This opportunity is particularly suited for organizations with expertise in medical product development, specifically those capable of designing and prototyping advanced wound care solutions with integrated antimicrobial and antifungal properties. The requirement for FDA approval underscores the need for regulatory experience and a robust quality assurance process. Contractors should be prepared to engage in research and development activities, prototype fabrication, and regulatory submission processes, all within the context of supporting military medical needs. For further details and access to solicitation documents, interested parties are encouraged to visit the official SAM.gov opportunity page at https://sam.gov/opp/e9ca2604fe0641d29fb9710826ba21a3/view.
Documents23